SEC Form 10-Q Summary
Issuer and period: The supplied filing is for Diffusion Pharmaceuticals Inc., not Cervomed Inc. It is an unaudited quarterly report for the three and six months ended June 30, 2018, filed August 10, 2018.
Business context
Diffusion is a clinical-stage biotechnology company with no product-sales revenue. Its lead candidate, trans sodium crocetinate (TSC), is being developed to improve the effectiveness of cancer treatments by addressing tumor hypoxia. The company was enrolling patients in a Phase 3 trial of TSC in newly diagnosed, inoperable glioblastoma (GBM). It was also developing plans for a proposed Phase 2 acute-stroke study, subject to funding. RES-529, another candidate, was in preclinical oncology development; the company was exploring options including out-licensing.
Financial position and results
| Metric | Period/value |
|---|---|
| Product revenue | None; the company reported no product-sales revenue. |
| Operating expenses | Q2 2018: $3.08 million, versus $2.98 million in Q2 2017. First half 2018: $6.43 million, versus $5.55 million in first half 2017. |
| Net income (loss) | Q2 2018: loss of $2.77 million, versus income of $20.39 million in Q2 2017. First half 2018: loss of $6.08 million, versus loss of $8.25 million in first half 2017. |
| Cash and cash equivalents | $12.93 million at June 30, 2018, compared with $8.90 million at December 31, 2017. |
| Cash flow | First-half operating cash used: $5.83 million. Investing cash flow: zero. Financing cash provided: $9.87 million. Net cash increase: $4.04 million. |
| Liquidity and debt | Working capital was $13.0 million. No debt was outstanding at June 30; the company repaid approximately $0.6 million of principal and $40,000 of interest during the first half. |
| Accumulated deficit and equity | Accumulated deficit: $67.63 million; stockholders’ equity: $27.30 million at June 30, 2018. |
Margins are not meaningful because the company had no product revenue. No clear gross-margin figure is provided.
Material changes versus prior periods
- First-half R&D expense increased $1.03 million year over year, mainly because of higher costs for the Phase 3 GBM trial; lower manufacturing costs partially offset the increase. Q2 R&D expense rose $0.21 million year over year.
- First-half G&A expense declined $0.19 million year over year, principally due to lower professional fees, partly offset by higher salary and other costs.
- The prior-year comparison included substantial noncash warrant-related gains and financing expenses. The 2017 Q2 net income included a $23.39 million gain from changes in warrant fair value; first-half 2017 included a $10.47 million warrant fair-value gain, $10.23 million of warrant-related expense, and $2.87 million of other financing expense. These items did not recur in 2018 after warrants were reclassified to equity.
- In January 2018, the company raised approximately $10.8 million net through a common-stock and warrant offering. Series A preferred stock converted into common stock, with additional shares issued for accrued dividends and a make-whole adjustment. The offering and conversion materially increased the share count: 50.57 million shares were outstanding at June 30, compared with 14.52 million at year-end 2017.
Outlook, risks and contingencies
- Management estimated that June 30 cash would fund operations into September 2019, but said additional funding would be needed to complete the Phase 3 GBM trial and support planned development. The company had no committed capital or borrowing facility and gave no assurance that financing would be available on acceptable terms.
- If financing is unavailable, the company may delay, scale back or discontinue programs, pursue collaborations or strategic alternatives, or cease operations. Further equity financing could dilute shareholders.
- On March 2, 2018, Nasdaq notified the company that its share price had been below $1.00 for 30 consecutive business days. The stated deadline to regain compliance was August 29, 2018; a reverse-split authorization of between 1-for-2 and 1-for-15 had been approved, with implementation left to the board.
- A former CEO’s arbitration-related matter remained unresolved. The company said it believed the claim was without merit but could not estimate a possible loss or its effect; it noted a potential material effect depending on outcome.
- Management reported disclosure controls and procedures were effective and no material change in internal control over financial reporting occurred during the quarter. The filing reported no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm issuer identity: the filing is for Diffusion Pharmaceuticals Inc., despite the request metadata naming Cervomed Inc.
- Check subsequent disclosures on Nasdaq minimum-bid compliance, any reverse split, and the company’s ability to raise capital after the stated deadline.
- Review updates on Phase 3 GBM enrollment, trial progress, expected costs and whether additional financing is required to complete the trial.
- Assess the dilutive potential of 31.31 million outstanding common-stock warrants and 3.21 million stock options reported at June 30, 2018.
- Monitor the former CEO arbitration matter and any later estimate or disclosure of potential loss.